DUBLIN--(BUSINESS WIRE)--The "Hereditary Angioedema: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Hereditary Angioedema estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 7.7% over the analysis period 2020-2027.
C1 Esterase Inhibitors, one of the segments analyzed in the report, is projected to record a 8.3% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Selective Bradykinin B2 Receptor Antagonists segment is readjusted to a revised 6.9% CAGR for the next 7-year period.
The U.S. Market is Estimated at $666 Million, While China is Forecast to Grow at 7.1% CAGR
The Hereditary Angioedema market in the U.S. is estimated at US$666 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$676.4 Million by the year 2027 trailing a CAGR of 7.1% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.8% and 6.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.
Kallikrein Inhibitors Segment to Record 8.9% CAGR
In the global Kallikrein Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 8.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$261.7 Million in the year 2020 will reach a projected size of US$478.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 46 Featured) -
- BioCryst Pharmaceuticals, Inc.
- CSL Ltd.
- iBio, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group NV
- Shire PLC
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Hereditary Angioedema - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/koibh1